JP2015525071A5 - - Google Patents

Download PDF

Info

Publication number
JP2015525071A5
JP2015525071A5 JP2015516160A JP2015516160A JP2015525071A5 JP 2015525071 A5 JP2015525071 A5 JP 2015525071A5 JP 2015516160 A JP2015516160 A JP 2015516160A JP 2015516160 A JP2015516160 A JP 2015516160A JP 2015525071 A5 JP2015525071 A5 JP 2015525071A5
Authority
JP
Japan
Prior art keywords
human
human immunoglobulin
chain variable
heavy chain
genetically engineered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015516160A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015525071A (ja
Filing date
Publication date
Priority claimed from US13/488,628 external-priority patent/US20130045492A1/en
Application filed filed Critical
Priority claimed from PCT/US2013/044257 external-priority patent/WO2013184761A1/en
Publication of JP2015525071A publication Critical patent/JP2015525071A/ja
Publication of JP2015525071A5 publication Critical patent/JP2015525071A5/ja
Pending legal-status Critical Current

Links

JP2015516160A 2012-06-05 2013-06-05 共通の軽鎖を用いて完全ヒト型二重特異性抗体を作製するための方法 Pending JP2015525071A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/488,628 US20130045492A1 (en) 2010-02-08 2012-06-05 Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US13/488,628 2012-06-05
PCT/US2013/044257 WO2013184761A1 (en) 2012-06-05 2013-06-05 Methods for making fully human bispecific antibodies using a common light chain

Publications (2)

Publication Number Publication Date
JP2015525071A JP2015525071A (ja) 2015-09-03
JP2015525071A5 true JP2015525071A5 (https=) 2016-07-21

Family

ID=48652344

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015516160A Pending JP2015525071A (ja) 2012-06-05 2013-06-05 共通の軽鎖を用いて完全ヒト型二重特異性抗体を作製するための方法

Country Status (12)

Country Link
EP (1) EP2854523A1 (https=)
JP (1) JP2015525071A (https=)
KR (1) KR20150023535A (https=)
CN (1) CN104582476B (https=)
AU (1) AU2013271737A1 (https=)
CA (1) CA2874846A1 (https=)
HK (1) HK1208994A1 (https=)
IL (1) IL235781A0 (https=)
MX (1) MX2014014891A (https=)
RU (1) RU2014153674A (https=)
SG (2) SG10201609535TA (https=)
WO (1) WO2013184761A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
EP2825036B1 (en) 2012-03-16 2018-05-02 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
WO2013138681A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
EP3539374A1 (en) 2012-03-16 2019-09-18 Regeneron Pharmaceuticals, Inc. Non-human animals expressing ph-sensitive immunoglobulin sequences
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
HK1218550A1 (zh) * 2013-03-13 2017-02-24 Regeneron Pharmaceuticals, Inc. 常見輕鏈小鼠
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
KR102614189B1 (ko) 2014-11-17 2023-12-18 리제너론 파아마슈티컬스, 인크. Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법
DK3221357T3 (da) * 2014-11-20 2020-08-10 Hoffmann La Roche Fælles letkæder og fremgangsmåder til anvendelse
EP3023437A1 (en) * 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
EP3885368A1 (en) 2015-05-12 2021-09-29 Regeneron Pharmaceuticals, Inc. Multimeric protein purity determination
AU2016325630B2 (en) * 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
KR20230006929A (ko) 2016-01-13 2023-01-11 리제너론 파마슈티칼스 인코포레이티드 조작된 중쇄 다양성 영역을 갖는 설치류
PT3773713T (pt) 2018-04-06 2025-07-29 Regeneron Pharma Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
CA3110513A1 (en) 2018-08-31 2020-03-05 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
US12583932B2 (en) * 2018-11-16 2026-03-24 Virtuoso Binco, Inc. CD38 and ICAM1 antibodies and uses thereof
BR112021016173A2 (pt) 2019-02-22 2021-11-03 Regeneron Pharma Roedor geneticamente modificado, métodos de produção de um roedor geneticamente modificado e de produção de um anticorpo anti-nav1.7, célula ou tecido isolado de roedor, linhagem celular imortalizada, embrião de roedor, construto de ácido nucleico de direcionamento, e, hibridoma
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US20220090060A1 (en) 2020-09-11 2022-03-24 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
CN116848254B (zh) 2020-12-16 2026-03-17 瑞泽恩制药公司 表达人源化Fcα受体的小鼠
IL303865A (en) 2020-12-23 2023-08-01 Regeneron Pharma Methods for obtaining antibodies that bind transmembrane proteins and cells that produce them
CA3165366A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
CN118496357A (zh) * 2023-02-15 2024-08-16 康源博创生物科技(北京)有限公司 一种多肽以及包含其作为轻链的抗体
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
WO2026035843A2 (en) 2024-08-06 2026-02-12 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68929167T2 (de) * 1988-09-06 2000-11-16 Xoma Corp., Berkeley Genexpressions-Elemente und Herstellung von chimären Maus-Mensch-Antikörpern
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH08509612A (ja) * 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
MXPA05000511A (es) * 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
PT1652920E (pt) * 2001-10-01 2010-11-08 Deutsches Krebsforsch Processo para a produção de bibliotecas de proteínas e para a selecção de proteínas a partir da mesma
WO2003061363A2 (en) * 2002-01-17 2003-07-31 Albert Einstein College Of Medicine Of Yeshiva University Mutations caused by activation-induced cytidine deaminase
ES2524767T3 (es) * 2002-06-14 2014-12-12 Immunomedics, Inc. Anticuerpo monoclonal humanizado HPAM4
CN101962408A (zh) * 2002-07-12 2011-02-02 杰斐逊·富特 超人源化抗体
EP2147594B1 (en) * 2008-06-27 2013-11-13 Merus B.V. Antibody producing non-human mammals
SMT202600080T1 (it) * 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
HUE047278T2 (hu) * 2011-08-05 2020-04-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek

Similar Documents

Publication Publication Date Title
JP2015525071A5 (https=)
JP2023011882A5 (https=)
RU2014153674A (ru) Способ получения полностью человеческих биспецифических антител с применением общей легкой цепи
JP7538907B2 (ja) 共通の軽鎖のマウス
JP2019076108A5 (https=)
JP2015502177A5 (https=)
JP2014110814A5 (https=)
JP2015509380A5 (https=)
JP2018138047A5 (https=)
JP2016512034A5 (https=)
JP2014524243A5 (https=)
RU2019121863A (ru) Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения
JP2015505477A5 (https=)
WO2014160202A4 (en) Mice expressing a limited immunoglobulin light chain repertoire
CN104244709B (zh) 共同轻链小鼠
JP2019076109A5 (https=)
JP2015510767A5 (https=)
JP2019047806A5 (https=)
JP2015519076A5 (https=)
KR101995753B1 (ko) 공통 경쇄를 가진 항체를 발현하는 비-사람 동물
RU2014127339A (ru) Мыши с гуманизированной легкой цепью
JP2021137030A5 (https=)
JP2013535213A5 (https=)
JP2017509355A5 (https=)
JP2008512987A5 (https=)